BPMC - Blueprint Medicines GAAP EPS of -$2.15 beats by $0.51 revenue of $63.28M beats by $21.43M

2023-05-04 07:55:35 ET

• Blueprint Medicines press release ( NASDAQ: BPMC ): Q1 GAAP EPS of -$2.15 beats by $0.51 .
• Revenue of $63.28M (+0.9% Y/Y) beats by $21.43M .
• Cash Position: As of March 31, 2023, cash, cash equivalents and investments were $961.3 million, as compared to $1,078.5 million as of December 31, 2022.
• 2023 Guidance: Blueprint Medicines has updated its financial guidance and now anticipates approximately $135 million to $145 million in AYVAKIT net product revenues for advanced SM and GIST in 2023, and $40 million to $50 million in collaboration revenues from existing collaborations in 2023. This guidance excludes revenue from the anticipated AYVAKIT indication expansion in ISM in mid-2023. The company continues to expect that its existing cash, cash equivalents and investments, together with anticipated future product revenues, will provide sufficient capital to enable the company to achieve a self-sustainable financial profile.

For further details see: